Showing results (1-10 of 6) with videos related to
Sort By:
Pageof 1
Clinical Drug Investigation|February 10, 2020
Correlations Among Subcutaneous Immunoglobulin Dosage, Immunoglobulin G Serum Pre-infusional Levels and Body Mass Index in Primary Antibody Deficiency Patients: A Pooled Analysis from the SHIFT/IBIS StudiesAntonio Pecoraro, Silvia Ricci, Alessandra Vultaggio, et al.Allergy, Asthma, and Clinical Immunology : Official Journal of the Canadian Society of Allergy and Clinical Immunology|September 18, 2020
Pediatric subset of primary immunodeficiency patients treated with SCIG: post hoc analysis of SHIFT and IBIS pooled dataViviana Moschese, Clementina Canessa, Antonino Trizzino, et al.Journal of the Neurological Sciences|August 21, 2025
Outcome measures in CIDP: A scoping and mapping reviewYusuf A Rajabally, Giorgio Maria Boggia, Danielle Riley, et al.Journal of the Peripheral Nervous System : JPNS|August 19, 2025
Real-World Multinational Survey of Chronic Inflammatory Demyelinating Polyneuropathy: Disease Characteristics and Therapeutic LandscapeLuis Querol, Simon Rinaldi, Andras Borsi, et al.Journal of Clinical Immunology|June 29, 2018
Biweekly Hizentra® in Primary Immunodeficiency: a Multicenter, Observational Cohort Study (IBIS)Alessandra Vultaggio, Chiara Azzari, Silvia Ricci, et al.Pediatric Allergy, Immunology, and Pulmonology|September 12, 2019
Subcutaneous Immunoglobulin Twenty Percent Every Two Weeks in Pediatric Patients with Primary Immunodeficiencies: Subcohort Analysis of the IBIS StudyClementina Canessa, Vera Gallo, Claudio Pignata, et al.Pageof 1